Biomarker ID 2503 |
Detailed information | |
---|---|
CancerLivER ID | 2503 |
Biomarker | Fibronectin, Tubulin-alpha-1 subunit, Matrix metalloproteinase 14, osteonectin SPARC, RAD23A, Ubiquitin-conjugating enzyme E2, Neutrophil-gelatinase associated lipocalin precursor lipocalin 2, TRAM protein, ADP/ATP carrier protein, High mobility group protein, Insulin stimulated protein kinase 1, Tr |
Biomarker Name/Symbol (given in Publication) | Fibronectin, Tubulin-alpha-1 subunit, Matrix metalloproteinase 14, osteonectin SPARC, RAD23A, Ubiquitin-conjugating enzyme E2, Neutrophil-gelatinase associated lipocalin precursor lipocalin 2, TRAM protein, ADP/ATP carrier protein, High mobility group protein, Insulin stimulated protein kinase 1, Transforming protein rhoA H12, Interferon gamma antagonist, Macrophage inhibitory cytokine 1, Betaine homocysteine S-methyltransferase, metalothionein-III, methylenetetrahydrofolate dehydrogease, metalloproteinase inhibitor1, aldehyde oxidase, uridine diphosphoglucose pyrophosphorylase, alpha-2 microglobulin, alpha-2 microglobulin receptor associated protein, TGF-beta, hepatocyte growth factor like protein, NGF-inducible anti-proliferative protein PC3, Early growth response protein 1, insulin like growth factor binding protein 3, insulin like growth factor binding protein 4, Interferon induced protein MXA, interferon-inducible protein 9-27, nuclear hormone receptor, plasminogen, haemoglobin alpha unit, decorin, c-myc oncogene, cyclin-dependent kinase inhibitor 1, DNA binding protein CPBP, transforming protein rho B, IgG, IgGK, IgG3, IgG1, IgG1K, IgA1, IgHA, IgG1-Fc, lymphocyte antigen |
Biomolecule | RNAs |
Subject | Human |
Degree of Validity | Potential diagnostic marker for HCC and diffrenetially expressed in HCC v/s non-tumor; but not validated on independent dataset |
Experimental Condition | HCC v/s non-tumor |
Cancer type | Hepatocellular carcinoma |
Regulation | Diffrenetially expressed in HCC v/s non-tumor |
Level of significance | p < 0.01 |
Source | Tissue |
PMID | 11973655 |
Type of Biomarker | Diagnostic |
Pathway | Metabolic pathways, growth factor, regulate immune response, cell cycle, traffiking pathways |
Cohort | 15 HCC patients: 8 HCV positive-HCC, 6 HBV-positive HCC and one HCV and HBV associated HCC. Histological analysis of non-tumour tissues showed that 11 HCCs had developed on cirrhotic and 4 on non-cirrhotic tissues; 5 well differentiated HCCs, and 10 moderately or poorly differentiated HCC. |
Sensitivity | NA |
Specificity | NA |
Accuracy | NA |
AUC | NA |
Disease | HCC v/s non-tumor |
Year of Publication | 2002 |
Clinical trial | NO |
Clinical trial (NCT Number) | NA |